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Abstract
The fibrinogen (Fg) binding MSCRAMM Clumping factor A (ClfA) from Staphylococcus aureus interacts with the C-terminal
region of the fibrinogen (Fg) c-chain. ClfA is the major virulence factor responsible for the observed clumping of S. aureus in
blood plasma and has been implicated as a virulence factor in a mouse model of septic arthritis and in rabbit and rat models
of infective endocarditis. We report here a high-resolution crystal structure of the ClfA ligand binding segment in complex
with a synthetic peptide mimicking the binding site in Fg. The residues in Fg required for binding to ClfA are identified from
this structure and from complementing biochemical studies. Furthermore, the platelet integrin aIIbb3 and ClfA bind to the
same segment in the Fg c-chain but the two cellular binding proteins recognize different residues in the common targeted
Fg segment. Based on these differences, we have identified peptides that selectively antagonize the ClfA-Fg interaction. The
ClfA-Fg binding mechanism is a variant of the ‘‘Dock, Lock and Latch’’ mechanism previously described for the
Staphylococcus epidermidis SdrG–Fg interaction. The structural insights gained from analyzing the ClfANFg peptide complex
and identifications of peptides that selectively recognize ClfA but not aIIbb3 may allow the design of novel anti-
staphylococcal agents. Our results also suggest that different MSCRAMMs with similar structural organization may have
originated from a common ancestor but have evolved to accommodate specific ligand structures.
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Introduction
Staphylococcus aureus is a Gram-positive commensal organism that
permanently colonizes 20% of healthy adults and transiently
colonizes up to 50% of the general population [1]. For many years,
S. aureus has been a major nosocomial pathogen causing a range of
diseases from superficial skin infections to life-threatening
conditions, including septicemia, endocarditis and pneumonia
[1,2]. Within the last decade a dramatic increase in the number of
invasive infections caused by community-acquired S. aureus have
been recorded in otherwise healthy children and young adults
[3,4]. This outbreak together with the continued increase in
antibiotic resistance among clinical strains underscores the need
for new prevention and treatment strategies [1].
A detailed characterization of the molecular pathogenesis of S.
aureus infections may expose new targets for the development of
novel therapeutics. Several staphylococcal virulence factors have
been identified including capsule, surface adhesins, proteases, and
toxins (reviewed in [5,6,7,8]). One of these virulence factors is the
MSCRAMM (microbial surface components recognizing adhesive
matrix molecules) clumping factor A (ClfA). ClfA is the major
staphylococcal fibrinogen (Fg) binding protein and is responsible
for the observed clumping of S. aureus in blood plasma [9,10].
Essentially all S. aureus clinical strains carry the clfA gene [11]; ClfA
is a virulence factor in a mouse model of septic arthritis [12] and in
rabbit and rat models of infective endocarditis [13,14,15].
ClfA generates strong immune responses and has shown
potential as a vaccine component in active and passive
immunization studies. In one study, mice vaccinated with a
recombinant ClfA segment containing the Fg-binding domain and
subsequently challenged with S. aureus showed significantly lower
levels of arthritis compared to mice vaccinated with a control
protein [12]. In another study, mice passively immunized with
polyclonal or monoclonal antibodies against the ClfA Fg-binding
domain were protected in a model of septic death [16]. The
humanized monoclonal antibody, AurexisH, has a high affinity for
ClfA and inhibits ClfA binding to Fg [17]. Aurexis is currently in
clinical trials in combination with antibiotic therapy for the
treatment of S. aureus bacteremia [18]. Thus ClfA is a viable target
for both vaccine and therapeutic strategies.
ClfA belongs to a class of cell wall-localized proteins that are
covalently anchored to the peptidoglycan [5,19,20]. Starting
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by the ligand-binding A region composed of three domains (N1,
N2, and N3), the serine-aspartate repeat domain (R region), and
C-terminal features required for cell wall anchoring such as the
LPXTG motif, a transmembrane segment and a short
cytoplasmic domain [21,22,23]. A crystal structure of a Fg-
binding ClfA segment (residues 221–559) which includes two of
the domains (N2N3) demonstrates that each domain adopts an
IgG-like fold [24]. This domain architecture was also deter-
mined from the crystal structure of the ligand binding segment
of SdrG from Staphylococcus epidermidis, an MSCRAMM that
binds to the N-terminal region of the Fg b-chain [25].
A dynamic mechanism of Fg binding termed ‘‘Dock, Lock
and Latch’’ (DLL) has been proposed for SdrG based on a
comparison of the crystal structures of SdrG N2N3 as an apo-
protein and in complex with a synthetic peptide mimicking the
targeted site in Fg [25]. In the SdrG DLL model, the apo-form
of the protein adopts an open conformation that allows the Fg
ligand access to a binding trench between the N2 and N3
domains. As the ligand peptide docks into the trench, a flexible
C-terminal extension of the N3 domain is redirected to cover
the ligand peptide and ‘‘lock’’ it in place. Subsequently the C-
terminal part of this extension interacts with the N2 domain and
forms a b-strand complementing a b-sheet in the N2 domain.
This inserted b-strand serves as a latch to form a stable
MSCRAMM ligand complex.
ClfA binds to the C-terminus of the Fg c-chain [10,23] and a
synthetic 17 amino acid peptide corresponding to this region was
shown to bind to ClfA. Interestingly, the A-region of the
staphylocccal MSCRAMM FnbpA protein also binds to the same
region in Fg [23]. Moreover residues in this Fg segment are also
targeted by the platelet aIIbb3 integrin [26,27,28] and a
recombinant form of ClfA has been shown to inhibit platelet
aggregation and the binding of platelets to immobilized Fg
[10,29,30].
The current study was undertaken to characterize the
interaction of ClfA and Fg to define in detail the binding of the
C-terminus of Fg’s c-chain and to explore if compounds can be
constructed that antagonize the ClfA-Fg interaction but does not
affect the Fg interaction with the platelet-integrin aIIbb3.
Results/Discussion
Identification of critical residues in Fg required for
binding to ClfA
In previous studies, a segment of ClfA composed of residues
221–559 was shown to bind to the C-terminal end of the human
Fg c-chain [10]. We designed, based on structural similarities with
SdrG, a smaller ClfA construct (229–545) predicted to be
composed only of the N2 N3 domains and showed that ClfA229–
545 retained the Fg-binding activity. To identify specific residues in
Fg that are important for binding to ClfA229–545, a panel of
peptides (Fig. 1A) based on the Fg c-chain sequence 395–411
(referred to as c
1–17) were synthesized in which each position was
sequentially substituted with an alanine residue (alanines 11 and
14 were changed to serines). These peptides were tested as
inhibitors in solid-phase binding assays, using a peptide concen-
tration giving about 50% inhibition by the wild-type peptide.
Peptides c
1–17
H6A, c
1–17
H7A, c
1–17
G10A, c
1–17
Q13A, c
1–17
A14S and
c
1–17
G15A were significantly less potent inhibitors than the native
sequence suggesting that the Fg residues H6, H7, G10, Q13, A14
and G15 interact with ClfA (Fig. 1B). Remarkably, peptides c
1–
17
A11S, c
1–17
D16A and c
1–17
V17A showed enhanced inhibition of
ClfA binding to a recombinant form of residues 395–411 of the Fg
c-chain fused to a GST protein (GST-Fg c1–17) compared to a
peptide with the wild-type sequence, indicating a higher affinity of
the peptide variants for ClfA.
The ability of ClfA229–545 to bind to the peptide containing the
c
1–17
D16A mutation was further characterized. In solid-phase
assays, ClfA binds to immobilized GST-Fg c
1–17 fusion protein
with a lower affinity (Kd=657 nM) compared to the mutated
GST-Fg c
1–17
D16A (Kd=35 nM) (Fig. 1C). In solution, using
isothermal titration calorimetry (ITC) assays, (Fig. 1D), ClfA also
binds with a lower affinity to the native c
1–17 peptide (Kd of
5.8 mM) compared to the mutant Fg c
1–17
D16A (Kd of 3 mM).
Thus, although the apparent dissociation constants differ accord-
ing to the assays used to estimate them, similar trends in affinity
between the wild-type and the D16A mutation were observed.
Our results showed that alanine substitution at the C-terminal
but not in the N-terminal region of the peptide affected
MSCRAMM binding suggesting that the ClfA binding site is
located at the very C-terminus of the Fg c-chain (Fig. 1). Results
also show that certain amino acid changes in the c
1–17 sequence
enhance ClfA binding compared to the wild-type Fg sequence
indicating that the human Fg c C-terminal 17 residues may not be
the optimum ligand for ClfA.
Analysis of the previously solved SdrG-Fg peptide complex
crystal structure showed that only 11 out of the 18 peptide residues
interacted with the MSCRAMM. Similarly, only a part of the 17-
residue c-chain segment may be required for binding to ClfA. In
order to establish the minimum Fg peptide required for binding to
ClfA229–545, a series of N- and C-terminal truncations of the c
1–
17
D16A peptide were synthesized (Fig. 2A). Truncations of 2, 4, 6 or
8 amino acids at the N-terminus of the Fg c-peptide resulted in a
reduced but detectable binding affinity when tested using ITC.
There was a direct relationship between the length of the peptide
and its affinity for ClfA. The smaller the peptide, the lower was the
observed affinity for the MSCRAMM (Fig. 2B). Thus, the N-
terminal residues of the Fg peptide (residues 1–8) are not critical
for the interaction but may either contribute to or stabilize the
binding of the peptide to ClfA. On the other hand, deletions of 2
or 4 residues from the C-terminal end of the c
1–17
D16A peptide
abolished binding. These results indicate that the C-terminal
amino acids of Fg are critical for binding to ClfA and are in
agreement with a previous report that showed that Fg lacking the
Author Summary
Staphylococcus aureus (S. aureus) is a common pathogen
that can cause a range of diseases from mild skin infections
to life-threatening sepsis in humans. Some surface proteins
on S. aureus play important roles in the S. aureus disease
process. One of these bacterial surface proteins is
clumping factor A (ClfA) that binds to the C-terminal
region of one of the three chains of fibrinogen (Fg), a
blood protein that plays a key role in coagulation. We
carried out biochemical and structural studies to under-
stand the binding mechanism of ClfA to Fg and to define
the residues in Fg that interact with ClfA. Interestingly, the
platelet integrin, which is important for platelet aggrega-
tion and thrombi formation, also binds to the same region
of Fg as ClfA. Despite the fact that the two proteins bind at
the same region, the mode of recognition is significantly
different. Exploiting this difference in recognition, we have
demonstrated that agents could be designed that inhibit
the ClfA–Fg interaction but do not interfere with the
interaction of Fg with the platelet integrin. This opens the
field for the design of a novel class of anti-staph
therapeutics.
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residues 14–17 in the peptide) or a Fg-variant that replaces the last
four c-chain residues with 20 amino acids lacks the ability to bind
recombinant ClfA221–550 and induce S. aureus clumping [10].
A stabilized closed conformation of ClfA229–545 binds Fg
with a higher affinity than the open form
The Fg binding mechanism of SdrG276–596 involves a transition
from an open conformation, where the peptide binding trench
between the N2 and N3 domains is exposed for ligand docking, to
a closed conformation of the SdrG276–596 seen for the
MSCRAMM in complex with the ligand peptide. The insertion
of the N3 extension into the latching trench on N2, which
represents the last step in the dynamic DLL binding mechanism,
stabilizes the closed conformation of SdrG237–596 [31]. A closed
conformation of apo SdrG N2N3, stabilized by introducing a
disulfide bond between the end of the N3 latch and the ‘‘bottom’’
of N2, no longer binds Fg [31] demonstrating that for SdrG an
open conformation is required for the initial docking of the ligand
peptide. To explore if the binding of ClfA to Fg is also dependent
on a movement of the latch we constructed a ClfA protein
containing two cysteine substitutions. The locations of the cysteine
mutations were determined using computer modeling and by
sequence alignment to corresponding mutations in SdrG [31]. The
mutant ClfAD327C/K541C generated a stable, closed conformation
form. This recombinant His-tag fusion protein was purified by Ni
+
chelating chromatography; ion-exchange and gel permeation
chromatography. The ClfAD327C/K541C open and closed confor-
mation forms were examined by SDS-PAGE analysis (Fig. 2C).
Under non reducing conditions, the disulfide bonded closed form
of ClfAD327C/K541C migrated faster on SDS-PAGE than its non-
disulfide bonded open form. Presumably, under non-reducing
conditions, closed conformation mutants are more compact and
migrate faster on SDS-PAGE than open conformation constructs.
Under reducing conditions, the disulfide mutant and the wild-type
protein migrate at the same rate. Surprisingly, the closed
conformation of the disulfide mutant ClfAD327C/K541C was able
to bind Fg (Fig. 2C). Elisa-type binding assays where Fg or GST
Figure 1. ClfA229–545 binds to Fg c chain peptides. (A) Panel of Fg c-chain peptides. The wild-type peptide corresponds to the 17 C-terminal
residues of the Fg c-chain (395–411); the mutated peptides have individual amino acids replaced with Ala (or Ser). (B) Fg c peptides inhibit ClfA
binding to immobilized GST-Fg c
1–17 in solid phase assays. Wells were coated with 1 mg GST- Fg c
1–17 peptide. ClfA229–545 (100 nM) was pre-
incubated with wild-type Fg c
1–17 peptide (WT c
1–17) or the P1 (G1A) to P17 (V17A) mutant peptide (50 mM) for 1 hr. (C) Binding of ClfA to
immobilized GST-Fg c
1–17 and GST-Fg c
1–17
D16A using a solid-phase assay. Increasing concentrations of rClfA229–545 were incubated in microtiter wells
containing 1 mg GST (circles), GST-Fg c
1–17 (triangles) or GST-Fg c
1–17
D16A (squares). Bound ClfA was detected with anti-His monoclonal antibodies as
described in Material and Methods. (D) Binding of ClfA229–545 to Fg c
1–17 and Fg c
1–17
D16A peptides in solution using ITC.
doi:10.1371/journal.ppat.1000226.g001
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1–17 peptide were coated in microtiter wells and incubated
with ClfA showed that the closed conformation ClfAD327C/K541C
bound the ligand with a much lower apparent Kd (34 nM Fg;
20 nM GST-Fg c
1–17) compared to the wild-type ClfA229–545
(apparent Kd 305 nM Fg; 222 nM GST-Fg c
1–17) (Fig. 2D). These
results demonstrate that an open conformation may not be
required for Fg binding to ClfA and that Fg binding by ClfA
involves a mechanism that is different from the DLL mechanism
employed by SdrG.
Crystal structure of ClfA(229–545)D327C/K541C in complex
with a 13 residue Fg-derived peptide
Crystallization screens were carried out with ClfAD327C/K541C
in complex with several N-terminal truncations of the c
1–17
D16A
peptide that were shown to bind ClfA. Crystals of the stable closed
conformation of ClfA229–545 in complex with several peptides were
obtained, but structure determination was attempted for only the
ClfA(229–545)D327C/K541C-c
5–17
D16A peptide. The crystals of the
ClfA-peptide complex diffracted to a 1.95 A ˚ resolution. Two
copies of the ClfA-peptide complex were found in the asymmetric
part of the unit cell and are referred to as A:C and B:D. Although
the 13 residue Fg c
5–17 chain synthetic peptide was used for
crystallization, only 11 residues were identified completely in both
copies of the complex. The two molecules of ClfAD327C/K541C (A
and B) are nearly identical with rms deviation of 0.3 A ˚ for 312 Ca
atoms and 0.55 A ˚ for backbone atoms. As observed in the apo-
ClfA221–559 structure [24], the ClfA(229–545)D327C/K541C N2 and
N3 domains adopt the DE-variant IgG fold. The overall structure
of the ClfAD327C/K541C peptide complex (A:C) and the two
different orientations of the complex are shown in Figure 3A and
3B respectively. The C-terminal extension of the N3 domain
makes a b-sheet complementation with strand E of the N2
Figure 2. Fg and Fg c
1–17
D16A peptide truncations binding to different forms of ClfA. (A) Panel of Fg c
1–17
D16A peptides with N- and C-
terminal truncations. (B) N-terminal deletions of Fg c
1–17
D16A peptide bind ClfA229–545 with decreasing affinities. N- and C-terminal truncated Fg c
1–
17
D16A peptides were tested for their ability to bind ClfA229–545 in solution using ITC. (C) A stable closed conformation ClfA229–545 was engineered by
introducing a disulfide bridge. The left panel shows a ligand blot of rClfAD327C/K541C. Recombinant proteins were run in an SDS-PAGE in the presence
or absence of 5 mM DTT and stained with Coomassie Blue (left panel) or transferred to a PDVF membrane (middle panel). Transferred proteins were
probed with Fg (10 mg/ml) and detected with anti-Fg and AP-conjugated secondary antibodies. (Right panel) The purified closed form of ClfA327C/
541C used for crystallization and ClfA229–545 were run in an SDS-PAGE and stained with Coomassie Blue (right panel). (D) The closed conformation of
ClfAD327C/K541C binds immobilized Fg and GST-Fg c
1–17
D16A. ClfA229–545 or ClfAD327C/K541C was incubated with wells coated with either Fg or GST-Fg c
1–
17
D16A and detected with anti-His monoclonal antibodies as described in Materials and Methods.
doi:10.1371/journal.ppat.1000226.g002
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bond as predicted by SDS-PAGE analysis (Fig. 2C) and confirmed
by the crystal structure (Fig. S1). The two copies of the Fg c-
peptide molecules are nearly identical with rms deviation of 0.5 A ˚
for 11 Ca atoms and 0.89 A ˚ for backbone atoms. The interaction
between the ClfAD327C/K541C and the peptide buries a total
surface area of 1849 A ˚ 2 and 1826 A ˚ 2 in the A:C and B:D
complex, respectively. The interaction of the peptide with the N2
domain is predominantly hydrophobic in nature, in addition to a
few main-chain hydrogen bonds (Fig. 3C). Interactions between
the Fg peptide and the N3 domain are both hydrophobic and
electrostatic with the electrostatic contribution coming almost
entirely from the main chain-main chain hydrogen bonds due to
the parallel b-sheet formation of the peptide with strand G of the
N3 domain (Fig. 3C). The side-chain interactions between the
peptide and ClfA are predominantly hydrophobic. The 11 C-
terminal residues of the Fg c-chain peptide sequence that interact
with ClfA are composed of only two polar residues, Lys12 and
Gln13. Side chain atoms of Lys12 point away and do not interact
with the ClfA protein whereas Gln13 makes two hydrogen bonds
with the main chain atoms of Ile384 in ClfA (Fig. 3D). A water-
mediated interaction is also observed between Gln13 of the
peptide and Asn525 of ClfA. Tyr338 in the N2 domain and
Trp523 in the N3 domain play an important role in anchoring the
peptide molecule. Tyr338 and Trp523 are stacked with residues
Gly15 and Gly10, respectively. In addition, Met521 and Phe529
make hydrophobic interactions with Ala7 and Val17, respectively.
The C-terminal residues of the peptide Ala14, Gly15, Ala16, and
Val17 are buried between the N2–N3 domain interface with the
terminal Val residue, presumably threaded through a preformed
Figure 3. Representation of ClfAD327C/K541C (N2–N3)-peptide complex. (A) Ribbon representation of ClfA-peptide (Fg c-chain analog)
complex. The peptide is shown as ball and stick model. 2Fo-Fc map around the peptide contoured at 1s is shown in the close-up view. (B) Ribbon
representation of ClfAD327C/K541C –peptide complex in two orientations. The peptide molecule is shown in red and the engineered disulfide bond is
shown as blue ball-and-stick object. (C) Schematic representation of ClfA-Fg c-peptide main-chain parallel b-complementation interaction. The anti-
parallel b-complementation observed in SdrG273–597-Fg b-peptide complex is also shown for comparison. The residue numbers of both the Fg c-chain
sequence and the peptide numbering (1–17), in parenthesis, are shown. (D) Stereo-view showing the side-chain interactions of the ClfA- Fg c-
peptide complex. Carbon atoms of the peptide are shown in grey; oxygen, red; nitrogen, blue. Side chain atoms of ClfA are shown as pink stick
objects. Hydrogen bonds are shown as dotted lines.
doi:10.1371/journal.ppat.1000226.g003
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conformation. A hydrogen bond is observed between Lys389 of
ClfA and the C-terminal carboxyl group of the peptide (Fig. 3D).
Mutational studies showed that Tyr338Ala and Lys389Ala mutant
ClfA showed significantly reduced binding to Fg [24] which
corroborates with the structural results. Also an earlier study
showed that E526A and V527S affected the binding [32]. The
structure shows that these residues make main-chain interactions
with the peptide (Fig. 3C). These residues are critical for the
anchoring the peptide (Lock) and redirection of the latch.
Structural differences between the closed conformation
ClfAD327C/K541C-peptide complex and the apo-ClfA221–559
protein
The individual N2 and N3 domains in the apo-ClfA221–559 and
the closed form of ClfAD327C/K541C are almost identical with rms
deviations of 0.33 and 0.42 A ˚ for molecule A and 0.35 and 0.42 A ˚
for molecule B, but the relative orientation of the N2 and N3
domains are significantly different (Fig. 4A). This difference affects
the association of the N2 and N3 domains. In the apo conformation,
the buried surface area between the N2 and N3 domains is 87 A ˚ 2
compared to 367 A ˚ 2 in the closed form of the ClfA(221–559)D327C/
K541C-peptide complex. In the apo-ClfA221–559, the C-terminal
residues (Ala528-Glu559) of the N3 domain fold back and do not
interact with the N2 domain. Moreover the folded-back segment
completely occupies the binding site (Fig. 4B). Therefore, in the
folded-back conformation, the ligand binding site appears not to be
accessible to the peptide and thus this conformation appears to be
inactive. It is presently unclear what the spatial arrangements of the
N2N3 domains are in intact ClfA expressed on the surface of a
staphylococcal cell. The two structures of these domains solved sofar
where one is active and the other inactive form suggests a possible
regulation of ClfA’s Fg binding activity by external factors.One such
factormaybeCa
2+whichhasbeenshowntoinhibitClfA-Fgbinding
[32]. Alternatively, it is possible that the folded-back conformation
(which is a larger protein construct) is only one of the many possible
conformations adopted by the unbound protein. Molecular
modeling shows that the two domains in the folded-back
conformation could adopt an orientation similar to their orientation
in the ClfA-peptide complex (Fig. S2). Most likely, the structural
rearrangements responsible for the transition of ClfA from an open
unboundto theclosedboundformarecomplexand involvedifferent
intermediate forms.
Structural similarities/differences between the closed
form of the ClfA-peptide and SdrG-peptide complexes
The major difference between Fg-binding to ClfA and SdrG is
that the directionality of the bound ligand peptide is reversed
Figure 4. Superposition of apo-ClfA, ClfA-peptide and SdrG-peptide structures. (A) Superposition of apo-ClfA221–559, ClfAD327C/K541C -
peptide complex. The N3 domains of the two structures are superposed showing significant deviation in the inter-domain orientations. Apo-ClfA is
shown as a cyan ribbon object and ClfA-peptide complex is shown in green. (B) Only N3 domain of apo-ClfA (cyan) is shown for clarity. The folded-
back residues of the C-terminal residues of the apo-ClfA are shown in purple. The Fg c-chain peptide is shown as red ribbon. (C) Superposition of
ClfA-peptide and SdrG-peptide complexes. The peptide molecules corresponding to ClfA and SdrG complexes are shown as red and blue ribbon
objects respectively. ClfA is colored by secondary structure and SdrG is shown as thin yellow uniform coil.
doi:10.1371/journal.ppat.1000226.g004
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the N2 and N3 in ClfA and makes a parallel b-sheet
complementation with strand G of the N3 domain, whereas in
SdrG, the N-terminal residues of the ligand are docked between
the N2 and N3 domains and form an anti-parallel b-sheet with the
G strand. In both cases there are 11 ligand residues that make
extensive contact with the MSCRAMM but with one residue
shifted towards the N3 domain in ClfA. Of these 11 residues, 7
and 11 residues participate in the b-strand complementation of
SdrG and ClfA, respectively. Although the peptide binding model
of ClfA is different to that of SdrG, the inter-domain orientations
of the two MSCRAMMS are very similar [25]. Superposition of
302 corresponding atoms in the N2 and N3 domains of ClfA and
SdrG showed a small rms deviation of 0.65 A ˚ indicating the high
structural similarity between the two MSCRAMMS. Another
striking difference is that ClfA does not require an open-
conformation for ligand binding, whereas Fg can not bind to a
stabilized closed conformation of SdrG. ClfA binds the C-terminal
end of Fg and the last few residues of the c-chain presumably can
be threaded in to the binding pocket. In the SdrG-Fg interaction,
the binding segment in Fg does not involve the seven N-terminal
residues of the ligand and therefore an open conformation may be
required for ligand binding.
Comparison of Fg binding to ClfA and the platelet
integrin aIIbb3
The C-terminus of Fg c-chain, which is targeted by ClfA, is also
recognized by the aIIbb3 integrin in Fg induced platelet
aggregation, a vital step in thrombosis [10,33]. The Fg c-chain
complex with aIIbb3 structure is not available but structures of
related complexes provide clues on how aIIbb3 likely interact with
Fg [34]. In addition, the crystal structure of the avb3 integrin in
complex with an RGD ligand provided a structural model of a
similar ligand-integrin interaction [35]. In this structure, the Asp
(D) residue of the RGD sequence coordinates with the metal ion in
the Metal Ion Dependent Adhesion Site (MIDAS) of the integrin
and thus plays a key role in the interaction. The platelet specific
integrin aIIbb3 recognizes ligands with an RGD sequence or the
sequence Lys-Gln-Ala-Gly-Asp-Val found in Fg [34]. Structural
studies with drug molecules that antagonize the integrin-RGD or -
Fg interaction showed that each of the drug molecules contains a
carboxyl group moiety that mimics the aspartic acid and a basic
group that mimics the Arg (or Lys in the case of Fg) in the ligand
[34]. These results suggest that the Lys and Asp residues in the C-
terminal c-chain sequence are critical for the interaction with
integrin. Interestingly, our studies have shown that these Lys and
Asp residues in Fg are not critical for ClfA binding (Fig. 1B). In
fact, substitution of Asp with Ala (c
1–17
D16A) results in a higher
binding affinity. Absence of a strong interaction with Lys12 in the
ClfA-peptide complex structure also correlates with the biochem-
ical data, suggesting that Arg is not a key player in the ClfA-Fg
interaction. In general, our studies show that K406 and D410,
which are essential for the platelet integrin aIIbb3-Fg interaction,
are dispensable for the ClfA-Fg interaction. To experimentally
examine this proposed difference, the ability of the synthesized Fg
WT c
1–17 and mutated peptides (c
1–17
D16A and c
1–17
K12A)t o
inhibit full length Fg binding to aIIbb3 was analyzed by an
inhibitory ELISA type assay (Fig. 5). The WT c
1–17 peptide
completely inhibited the binding of full-length fibrinogen to aIIbb3
whereas c
1–17
D16A and c
1–17
K12A weakly inhibited Fg binding to
aIIbb3. These results clearly demonstrated that the c
1–17
D16A and
c
1–17
K12A peptides bind weakly to platelet integrin and therefore
could serve as specific antagonists of Fg-ClfA interaction.
Conclusions
Based on the results presented here, we postulate that the
mechanism of interaction between ClfA and Fg is a variation of
the ‘‘Dock, Lock and Latch (DLL)’’ model of SdrG binding to Fg.
In the DLL model of binding, the apo-form of the SdrG is in an
open conformation to allow the ligand access to the binding cleft.
A closed conformation of SdrG is unable to bind Fg. In the ClfA
model, we believe that the peptide may thread into the cavity
formed in a stabilized closed configuration and therefore the ClfA-
Fg binding mechanism could be called ‘‘Latch and Dock’’.
In the case of CNA, a collagen binding MSCRAMM from S.
aureus, the collagen molecule binds to CNA through a ‘‘collagen
hug’’ model [36] which represents yet another variant of the DLL
binding mechanism. All three MSCRAMM-ligand structures
determined so far, SdrG, CNA and the ClfA have different ligand
binding characteristics and mechanisms, although the overall
structures of the ligand binding regions of these MSCRAMMs are
very similar. These observations suggest that an ancestral
MSCRAMM has evolved along different paths to accommodate
different ligands without greatly altering the overall organization
of the proteins.
The co-crystal structure of ClfA in complex with the C-terminal
region of the c-chain of Fg will allow the design of potent antagonist
of the ClfA-Fg interaction. The Fg based peptide analogs that
antagonize the ClfA-Fg interaction but not affect the aIIbb3 integrin
interaction could serve as a starting point to develop novel anti-
staphylococcal therapeutic agents that do not affect the aIIbb3.
Materials and Methods
Bacterial Strains, Plasmids, and Culture Conditions
Escherichia coli XL-1 Blue (Stratagene) was used as the host for
plasmid cloning and protein expression. Chromosomal DNA from
S. aureus strain Newman was used to amplify the ClfA DNA
sequence. All E. coli strains containing plasmids were grown on LB
media with ampicillin (100 mg/ml).
Manipulation of DNA
DNA restriction enzymes were used according to the manufac-
turer’s protocols (New England Biolabs) and DNA manipulations
Figure 5. The c
1–17
D16A and c
1–17
K12A peptides bind weakly to
platelet integrin aIIbb3. Inhibition of Fg c peptides (c
1–17
D16A, c
1–
17
K12A and WT c
1–17) on binding of full length Fg to immobilized aIIbb3.
Wild-type Fg-c
1–17 peptide (circle) inhibits Fg binding to aIIbb3 whereas
c
1–17
D16A (triangle) and c
1–17
K12A (square) peptides have very little
inhibitory effect. Various concentrations of peptides were mixed with a
fixed Fg concentration (10 nM) and the mixture added to immobilized
aIIbb3. Bound Fg was detected using antibodies against human Fg as
described in Materials and Methods.
doi:10.1371/journal.ppat.1000226.g005
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used for cloning and sequencing was purified using the Qiagen
Miniprep kit (Qiagen). DNA was sequenced by the dideoxy chain
termination method with an ABI 373A DNA Sequencer (Perkin
Elmer, Applied Biosystems Division). DNA containing the N-
terminal ClfA sequences were amplified by PCR (Applied
Biosystems) using Newman strain chromosomal DNA as previ-
ously described [38]. The synthetic oligonucleotides (IDT) used for
amplifying clfA gene products are listed in Table S1.
Construction of disulfide mutants
Cysteine mutations were predicted by comparing ClfA221–559 to
SdrG(273–597) disulfide mutant with stable closed conformations
[31] and by computer modeling. A model of ClfA in closed
conformation was built based on the closed conformation of the
SdrG-peptide complex [25]. The Cb-Cb distances were calculated
for a few residues at the C-terminal end of the latch and strand E
in the N2 domain. Residue pairs with Cb-Cb distance less than
3A ˚ were changed to cysteines to identify residues that could form
optimum disulfide bond geometry. The D327C/K541C mutant
was found to form a disulfide bond at the end of the latch. The
cysteine mutations in ClfAD327C/K541C were generated by overlap
PCR [39,40]. The forward primer for PCR extension contained a
BamHI restriction site and the reverse primer contained a KpnI
restriction site. The mutagenesis primers contained complemen-
tary overlapping sequences. The final PCR product was digested
with BamHI and KpnI and was ligated into same site in the
expression vector pQE-30 (Qiagen). All mutations were confirmed
by sequencing. The primers used are listed in Table S1.
Expression and Purification of Recombinant Proteins
E. coli lysates containing recombinant ClfA and GST-Fg c-chain
fusion proteins were purified as previously described [32]. PCR
products were subcloned into expression vector pQE-30 (Qiagen)
to generate recombinant proteins containing an N-terminal
histidine (His) tag as previously described [10]. The recombinant
ClfA His-tag fusion proteins were purified by metal chelation
chromatography and anion exchange chromatography as previ-
ously described [23]. To generate recombinant ClfA229–545 and
ClfA221–559 proteins, PCR-amplified fragments were digested with
BamHI and KpnI and cloned into BamHI/KpnI digested pQE-30.
The primers used to generate the recombinant constructs are listed
in Table S1. The reactions contained 50 ng of strain Newman
DNA, 100 pmol of each forward and reverse primers, 250 nM of
each dNTP, 2 units of Pfu DNA polymerase (Stratagene) and 5 ml
Pfu buffer in a total volume of 50 ml. The DNA was amplified at
94uC for 1 min, 48uC for 45 sec; 72uC for 2 min for 30 cycles,
followed by 72uC for 10 min. The PCR products were analyzed
by agarose gel electrophoresis using standard methods [37] and
purified as described above.
Enzyme-linked Immunosorbent Assay
The ability of the wild-type ClfA229–545 and disulfide ClfA
mutants to bind Fg was analyzed by ELISA-type binding assays.
Immulon 4HBX Microtiter plates (Thermo) were coated with
human Fg (1 mg/well) in HBS (10 mM HEPES, 100 mM NaCl,
3 mM EDTA, pH 7.4) over-night at 4uC. The wells were washed
with HBS containing 0.05% (w/v) Tween-20 (HBST) and blocked
with 5% (w/v) BSA in HBS for 1 h at 25uC. The wells were
washed 3 times with HBST and recombinant ClfA proteins in
HBS were added and the plates were incubated at 25uC for 1 h.
After incubation, the plates were washed 3 times with HBST.
Anti-His antibodies (GE Healthcare) were added (1:3000 in HBS)
and the plates were incubated at 25uC for 1 h. The wells were
subsequently washed 3 times with HBST and incubated with goat
anti-mouse-AP secondary antibodies (diluted 1:3000 in HBS; Bio-
Rad) at 25uC for 1 h. The wells were washed 3 times with HBST
and AP-conjugated polyclonal antibodies were detected by
addition of p-nitrophenyl phosphate (Sigma) in 1 M diethanol-
amine (0.5 mM MgCl2, pH 9.8) and incubated at 25uC for 30–
60 min. The plates were read at 405 nm in a ELISA plate reader
(Thermomax, Molecular Devices). For the inhibition assays,
recombinant ClfA229–545 was pre-incubated with Fg c peptides
in HBS for 1 h at 37uC. The recombinant protein-peptide
solutions were then added to plates coated with 1 mg/well GST
fusion protein containing the native human Fg c 395–411
sequence (called GST-Fg c
1–17) and bound protein was detected
as described above. If the peptide binds ClfA it would inhibit
binding of the GST-Fg c
1–17 to the MSCRAMM.
For aIIbb3 inhibition assay, Immulon 4HBX Microtiter 96-well
plates (Thermo) were coated with aIIbb3 (0.25 mg/well) in TBS
(25 mM Tris, 3 mM KCl, 140 mM NaCl, pH 7.4) over night at
4uC. The wells were washed with TBS containing 0.05% (w/v)
Tween-20 (TBST). After blocking with 3% (w/v) BSA dissolved in
TBS for 1 h at RT, 10 nM of full length Fg was applied in the
presence of either WT c
1–17, c
1–17
D16A or c
1–17
K12A peptides and
plates were incubated at RT for another hour. The bound full
length Fg was then detected by goat anti human Fg (1:1000
dilution, Sigma) antibody followed by horseradish peroxidase-
conjugated rabbit anti-goat IgG antibody (1:1000 dilution,
Cappel). After incubation with 0.4 mg/ml of substrate, o-
phenylenediamine dihydrochloride (OPD, Sigma) dissolved in
phosphate-citrate buffer, pH 5.0, bound antibodies were deter-
mined in an ELISA reader at 450 nm. The proteins, antibodies
and peptides were diluted in TBST containing 1% (w/v) BSA,
2 mM MgCl2, 1 mM of CaCl2 and MnCl2.
Synthesis of c-chain Peptides
The wild-type and mutated peptides corresponding to the 17 C-
terminal residues of the fibrinogen c-chain (395–411) and
truncated versions of this peptide (listed in Figure 2A) were
synthesized as previously described and purified using HPLC [10].
Isothermal Titration Calorimetry
The interaction between ClfA proteins and soluble Fg peptides
was analyzed by Isothermal titration calorimetry (ITC) using a
VP-ITC microcalorimeter (MicroCal). The cell contained 30 mM
ClfA and the syringe contained 500–600 mM peptide in HBS
buffer (10 mM HEPES, 150 mM NaCl, pH 7.4). All samples were
degassed for 5 min. The titration was performed at 30uC using a
preliminary injection of 5 ml followed by 30 injections of 10 ml
with an injection speed of 0.5 ml/sec. The stirring speed was
300 rpm. Data were fitted to a single binding site model and
analyzed using Origin version 5 (MicroCal) software.
Crystallization
The ClfAD327C/K541C protein was purified as described earlier
and concentrated to 30 mg/ml. The synthetic c-chain peptide
analogs, P16 and N-terminal truncations of P16 (P16 -2Nt, P16 -
4Nt and P16 -6Nt) were mixed with the protein at 1:20 molar ratio
and left for 30 min at 5u C. This mixture was screened for
crystallization conditions. Small needles of the ClfA/P16 -2Nt, -
4Nt and -6Nt were obtained during initial search of the
crystallization condition, but we could only successfully optimize
ClfA/P16 -4Nt and ClfA/P16 -6Nt. Diffraction quality crystals
were obtained by mixing 2 ml of protein solution with 2 mlo f
reservoir solution containing 16–20% PEG 8K, 100 mM succinic
acid pH 6.0.
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Crystals of ClfA/ P16 -4Nt were flash frozen with a stabilizing
solution containing 20% glycerol. Diffraction data were measured
on Rigaku R-Axis IV
++ detector. A total of 180 frames were
collected at a detector distance of 120 mm with 1u oscillation.
Data were indexed, integrated and scaled using d*terk [41]. The
crystals diffracted to 1.95 A ˚ and the data statistics were listed in
Table 1. Calculation of the Matthews coefficient suggested the
presence of 2 copies of the molecule in the unit cell of the triclinic
cell. The structure was solved by molecular replacement (MR)
with the program PHASER [42] using individual N2 and N3
domains of ClfA as search model. Solutions for the N3 domain
were obtained for the two copies followed by the solutions of N2
domains. Data covering 2.5–15 A ˚ were used for the molecular
replacement solution. Electron density maps calculated during the
initial rounds of refinement showed interpretable density for 11
out of 13 peptide residues in both the copies of the complex.
Modeling building of the peptide and rebuilding of a few loop
regions were performed using the program COOT [43]. A few
cycles of ARP/WARP [44] were performed to improve the map
and for the building of water model. After a few cycles of
refinement using Refmac5.2 [45], electron density was clear for
only the backbone atoms for two remaining N-terminal residues of
the peptide molecule D and one residue for peptide C. The final
model of ClfA included residues 230–299, 303–452, 456–476 and
479–545 in molecule A and 230–438, 440–476 and 479–542 in
molecule B. The structure was refined to a final R-factor of 21.1%
and R-free of 27.9%. Stereochemical quality of the model was
validated using PROCHECK [46]. Molecular modeling studies
were performed using InsightII software (Accrelys Inc). Figures
were made using RIBBONS [47]. The atomic coordinates and
structure factors of the complex structure have been deposited in
Protein data bank with accession number; 2vr3.
Supporting Information
Figure S1 Stereo view showing the disulfide bond in the
ClfAD327C/K541C. 2Fo-Fc map around the Cys327 and
Cys541 contoured at 1s is shown. Carbon atoms are colored
grey and the sulfur atoms in yellow.
Found at: doi:10.1371/journal.ppat.1000226.s001 (5.03 MB TIF)
Figure S2 Ribbon representation of modeled ClfA229–559 in
ligand bound N2–N3 orientation. Residues that make clashes are
shown as stick objects. This model was built to understand if the
altered N2–N3 orientation of the apo-form of ClfA (Fig. 4A) is due
to the folded-back conformation, a model of the apo-ClfA221–559
was constructed with the folded-back N3 domain and the N2
domain adopting an N2–N3 orientation similar to that observed in
the closed form of the ClfA-peptide complex. This model shows
that Tyr338 in the N2 domain makes severe clashes with residues
Ser535 and Gly534 of the folded back segment. An alternate
conformation for these residues is unlikely due to spatial
constraints. Additional clashes were also observed between Ala
254 and Gly 536. Thus, it is unlikely that the two domains in the
folded-back conformation could adopt an orientation similar to
their orientation in the ClfA-peptide complex.
Found at: doi:10.1371/journal.ppat.1000226.s002 (9.32 MB TIF)
Table S1
Found at: doi:10.1371/journal.ppat.1000226.s003 (0.02 MB
DOC)
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